Home FDA labels 2d7e9f6a-0f22-b103-e063-6294a90a912f Lipo Flavonoid Ear Pain Relief Drops with 4% Lidocaine openFDA label record# This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)
Brand name Lipo Flavonoid Ear Pain Relief Drops with 4% Lidocaine
Generic name LIPO FLAVONOID EAR PAIN RELIEF DROPS WITH 4% LIDOCAINE
Manufacturer Clarion Brands LLC
Product type HUMAN OTC DRUG
SPL set ID 2d7e9f6a-0f21-b103-e063-6294a90a912f
SPL ID 2d7e9f6a-0f22-b103-e063-6294a90a912f
Version 1
Effective date 2025-02-06
Source export date 2026-10-30
Source partition 1
Source file https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
Source object key raw/openfda/drug-label/2026-10-30/772d0e4623a189b47f3ab71d7d51f9b3c89c5526f4cf3d218e1c921bb964b80c/drug-label-0001-of-0014.json.zip
Source manifest SHA-256 b11f1f6b476c7417db937215bf14307ef1a0b69465b42b411ad52f42ae36ead3
Import run 20261102T182004Z
Imported at 2026-11-02 18:28:56 Harmonized routes table Harmonized routes AURICULAR (OTIC)
Harmonized identifier links# Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
Harmonized identifiers page 1 of 1 · 11 matching rows.
Warnings cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings For external use only Flammable keep away from fire, sparks, and heated surfaces exposure to temperatures above 130°F may cause bursting store at room temperature in a dry place Do not use in large quantities, particularly over raw surfaces or blistered areas for more than one week without consulting a doctor if you have a hole in your ear drum or tubes in your ear
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.